Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Aug 9, 2018 • 8:08 AM EDT
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Aug 6, 2018 • 4:01 PM EDT
Ligand Reports Second Quarter 2018 Financial Results
Jul 9, 2018 • 9:00 AM EDT
Ligand to Report Second Quarter 2018 Results on August 6th
Aug 6, 2018 • 4:30pm EDT
See all events
Jun 19, 2018 • 8:30am PDT
3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121
Jun 6, 2018 • 8:00am EDT
New York, NY
Opthea doses first patient in phase 2a trial for OPT-302 in
diabetic macular edema https://t.co/As9DtRacQO
Seelos Therapeutics and $APRI announce merger; to advance portfolio that includes Ligand-partnered late-stage progr… https://t.co/TBtPrMugtj
Opthea meets primary safety objective with OPT-302 in Phase 1b diabetic macular edema clinical trial https://t.co/1o2nIrJBHs